Please sign in before continuing.

A61K41/0071

PYROPHEOPHORBIDE CONJUGATE AND USE THEREOF IN THE TREATMENT OF CANCER AND AS A FLUORESCENT MARKER

The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.

VISIBLE LIGHT-ACTIVATABLE NANOPARTICLES FOR CANCER IMMUNOTHERAPY AND USE THEREOF

Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

PHOTODYNAMIC THERAPY COMPOSITIONS AND METHODS OF TREATMENT THEREIN
20220354953 · 2022-11-10 ·

A composition and method directed to the treatment of sun exposed skin, wounds and microbial infections is provided.

Bladder cancer photodynamic therapeutic agents with off-on magnetic resonance imaging enhancement

Provided herein are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.

Atropisomers of halogenated tetraphenylbacteriochlorins and chlorins and their use in photodynamic therapy

This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7 and X.sup.8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X.sup.2, X.sup.4, X.sup.6 and X.sup.8 are halogens, and the meta-phenyl substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently chosen from —OH, —OR or —SO.sub.2R″, where R″ are each independently chosen from —Cl, —OH, -aminoacid, —OR, —NHR, or —NR.sub.2, where R are alkyl of 1 to 12 carbon atoms or R.sub.2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 on the same side of the plane defined by the macrocycle. The invention also relates to an anticancer and/or antimicrobial and/or antiviral pharmaceutical composition where atropisomers α.sub.4 and α.sub.3β are the main active ingredients, such that the mixture of atropisomers α.sub.4 and α.sub.3β constitutes more than 70% of the atropisomers present in the active ingredient and/or the atropisomer α.sub.4 constitutes more than 20% of the atropisomers present in the pharmaceutical composition.

ECO-FRIENDLY SMART PHOTOSENSITIZER AND PHOTO-STEM CELL THERAPY PRODUCT COMPRISING SAME
20230088872 · 2023-03-23 ·

The present invention provides an eco-friendly smart photosensitizer comprising a conjugate of hydroxypropyl methylcellulose and porfimer sodium photosensitizer, and a photo-stem cell therapy product comprising the photosensitizer. The photosensitizer of the present invention can be advantageously used in various fields including anticancer therapy, stem cell therapy, and the like, without side effects.

Devices and processes for Cherenkov-activated nuclear-targeted photodynamic therapy

Devices, materials, compounds, systems, and processes for Cherenkov-Activated Nuclear-Targeted Photodynamic Therapy that involves generating Cherenkov light within the tissue of a target volume and using this light to activate photosensitizing material that is located in the nucleus of cells of the target volume.

CONJUGATE OF PHTHALOCYANINE DYE AND ANTIBODY OR PEPTIDE

Objects of the present invention are to provide a novel phthalocyanine dye for use in photoimmunotherapy, and a method for producing the same, and to provide a conjugate of the above-described phthalocyanine dye and an antibody or a peptide. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided:

##STR00001## wherein X represents a substituent having a hydrophilic group at the terminus thereof; L.sub.3, L.sub.4, L.sub.5, and L.sub.6 each independently represent a divalent linking group; Y represents a group capable of binding to an antibody or a peptide; R.sub.3 represents a substituent, such as an alkyl group containing 1 to 6 carbon atoms, an alkoxy group containing 1 to 6 carbon atoms, a halogen atom, —SR.sub.11, —SOR.sub.12, an aryl group containing 6 to 10 carbon atoms, —N(R.sub.13)(R.sub.14), or —NO.sub.2, wherein when a plurality of R.sub.3s are present, the plurality of R.sub.3s may be identical to or different from one another; and s represents an integer of 0 to 4.

PHOTODYNAMIC THERAPY TREATMENT SUPPORT DEVICE

A photodynamic therapy treatment support device is provided with a light source and a distribution information output unit. The light source irradiates a photosensitive substance administered to a body of a subject with light of a specific wavelength bandwidth having energy capable of generating fluorescence from the photosensitive substance without advancing necroses of tumor cells. The distribution information output unit outputs information on a distribution state of the fluorescence generated from the photosensitive substance, based on the fluorescence generated from the photosensitive substance.

NON-PERIPHERAL QUATERNARY AMMONIUM-MODIFIED ZINC PHTHALOCYANINE AND PREPARATION METHOD AND USE THEREOF
20230075925 · 2023-03-09 ·

The present disclosure provides a non-peripheral quaternary ammonium-modified zinc phthalocyanine and a preparation method and use thereof, belonging to the field of preparation of photodynamic drugs or photosensitizers. The non-peripheral quaternary ammonium-modified zinc phthalocyanine can be used as a photosensitizer for a photodynamic therapy (PDT) and photodynamic diagnosis, and can also be used for a photodynamic-immune synergistic therapy. Due to a unique structure, the non-peripheral quaternary ammonium-modified zinc phthalocyanine can be combined with an immune checkpoint blocker to achieve an excellent synergistic anti-tumor effect, which has a significant prospect for use in treating a metastatic tumor.